The consensus among major polls before Tuesday’s midterm elections was that the Democrats will probably win a majority in the House of Representatives, and the Republicans will likely hold the Senate. (Politico) Of course, polls have been wrong before. (Business Insider)

A Democratic House and a Republican Senate could have a big impact on healthcare policy. It would likely grind implementation of President Donald Trump’s drug-pricing blueprint to a halt. A Democratic House would also mean little to no chance of cuts to Medicaid or a repeal of the Affordable Care Act. (Business Insider)

Another school of thought: while major drug-pricing policy changes would be unlikely, Trump could reach the aisle on smaller measures. Bills to increase transparency on pharmaceutical companies’ relationships with PBMs or on Medicare Part B could get Democratic support in the House. (Politico)

Major pharma companies are looking forward to a lame-duck session of Congress with a lobbying campaign to roll back mandated discounts for senior citizens, required by a bill passed in February that could cost the drug industry $1.9 billion. Critics say nixing the law would increase drug costs for seniors on Medicare. (Bloomberg)

Voters in Idaho, Nebraska, and Utah are going to the polls today to decide whether their states should expand Medicaid, while several other states have ballot measures on abortion and medical marijuana. (Stat) In New Jersey, Democrats have called in the cavalry to campaign for Sen. Bob Menendez, who is locked in a tough race with former Celgene executive Bob Hugin. (New York Times)